Entering text into the input field will update the search result below

AC Immune to launch first in-human study of PET tracer for Parkinson's in H2

Mar. 15, 2018 11:24 AM ETAC Immune SA (ACIU) StockBy: Douglas W. House, SA News Editor
  • AC Immune (NASDAQ:ACIU -0.4%) announces that it plans to initiate a first in-human study of its investigational PET imaging agent for Parkinson's disease (PD). The company says the agent is highly selective for alpha-synuclein aggregates, an established drug target for the disorder. The tracer will enable PD drug developers to monitor the efficacy of PD therapies.
  • The company has been collaborating with Biogen (BIIB +0.3%) on the program for almost two years on a non-exclusive basis.
  • Shares were up over 5% before retracing.

Recommended For You

More Trending News

About ACIU Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACIU--
AC Immune SA